SAN DIEGO, March 14, 2017 /PRNewswire/ — Today, DePuy Synthes*, part of the Johnson & Johnson Family of Companies, released a new report, “Improving the Value of Primary Total Knee Arthroplasty: the ATTUNE® Knee System,” that analyzes the ATTUNE Knee’s current clinical and economic data. The report concludes that in a value-based healthcare environment with cost constraints and growing procedure volumes, the value of a knee replacement implant is measured not only by how long the implant lasts (implant survivorship), but also through patient reported outcomes and the economic benefits of the procedure.

The report, which was released alongside the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego, is authored by David Fisher**, M.D., Director of the Total Joint Center of Excellence at OrthoIndy Hospital in Indianapolis, Indiana, and Professor David Parkin, an Honorary Visiting Professor at City, University of London and a Senior Visiting Fellow, Office of Health Economics.

The report analyzes approaches for evaluating primary total knee arthroplasty (TKA) from a clinical and health economic perspective, and assesses the current data from DePuy Synthes’ ATTUNE Knee Evidence Generation Program. This program, the largest of its kind in DePuy Synthes’ history, includes a wide range of data from company-initiated studies, investigator-initiated studies, independent studies and national joint registries.

In their analysis, Dr. Fisher and Professor Parkin conclude that, “Based on available data, the ATTUNE Knee appears to be advancing outcomes for patients and creating value for clinicians, providers and payors in a challenging and dynamic healthcare environment.”

Click to Tweet: New @DePuySynthes report released today demonstrates the clinical and economic value of the ATTUNE^® Knee System #AAOS17 http://bit.ly/2mjUTL8

This report comes at a time when the entire episode of patient care is a major focus for global healthcare providers, placing a laser-like focus on both improving patient outcomes and managing costs. The bundled payments program in the United States and the “Payments for Results” system in England are two examples of the drive to minimize the total cost of care while maintaining quality. Against this backdrop, data from a comprehensive evidence generation program can help provide evidence to support decisions about a device’s overall value.

“The success of any knee replacement is multifactorial, and the data on the ATTUNE Knee gives me confidence that I’m using a knee replacement that is delivering value for patients and the healthcare system,” said Dr. Fisher.

Added Professor Parkin: “Quality of life, as measured by patient reported outcomes, has been shown to be a driver of cost effectiveness in knee replacement. The evidence that I’ve seen about the effectiveness of the ATTUNE Knee in improving patient reported outcomes suggests it can deliver a better quality of life for patients compared to other leading knee systems. Therefore, the ATTUNE Knee may potentially play a role in helping reduce some of the healthcare and societal costs associated with knee osteoarthritis.”

According to the analysis, the ATTUNE Knee has thus far demonstrated favorable survivorship, improved patient reported outcomes versus other knee systems, as well as potential economic benefits:

• Survivorship: The published report from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man (NJR) showed that the ATTUNE Knee’s estimated cumulative percent revision was 1.39% at three years (98.61% survivorship) for 4,463 knees, comparing favorably to the class of Cemented Total Knee Arthroplasty that has an estimated cumulative percent revision of 1.50%¹. In addition, per the 2016 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), in which 4,831 ATTUNE Knees are being tracked, the ATTUNE Knee’s estimated cumulative percent revision was 0.5% (ATTUNE Cruciate Retaining Knee) and 0.4% (ATTUNE Posterior Stabilized Knee) at one year.² This compares favorably to the overall class of cemented TKA at one year, which has an estimated cumulative percent revision of 1.0 percent.² 
• Patient Reported Outcomes: DePuy Synthes has taken the lead in this area by helping generate and validate a new measure, the Patient’s Knee Implant Performance (PKIP), to specifically assess the functional status of a patient’s knee from their own perspective. Results of a study using PKIP as well as other commonly used generic and condition-specific patient reported outcome measures showed that, at one year, study participants implanted with the ATTUNE Knee had statistically significant improvements compared to other leading knee systems in terms of confidence in stability during activity, decreased anterior knee pain, activities of daily living and quality of life.³
• Health Economics: A U.S. hospital database analysis showed 39% lower odds of patient discharge to a skilled nursing facility when implanted with an ATTUNE Knee, compared to patients who received total knee replacement with a Triathlon® Knee.⁴ This may potentially impact patient satisfaction and reduce healthcare costs. Post discharge costs are a significant portion of the overall episode of care. One study showed that up to 35% of episodic costs were related to post hospital discharge care⁵ and another showed it was up to 50%.⁶

To read this report and learn more about ATTUNE Knee Evidence, visit www.ATTUNEevidence.com.

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the effectiveness and value of the ATTUNE Knee System. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; product efficacy or safety concerns resulting in product recalls or regulatory action; manufacturing difficulties and delays; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns for health care products and services; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.

**Consultant to DePuy Synthes Companies

The third party trademarks used herein are the trademarks of their respective owners.

DSUS/JRC/0217/2031 March 2017

References:

SAN DIEGO, March 14, 2017 /PRNewswire/ — Every patient moves differently, and now surgeons can take this into account when performing hip replacement surgery thanks to a new technology from Corin Group that helps determine the best positioning of an implant and its components based on how patients really move during daily activities.

Corin announced the U.S. launch of its Optimized Positioning System (OPS™) System at the American Academy of Orthopaedic Surgeons (AAOS) in San Diego. The technology may lead to one of the most significant changes to the way hip replacements are performed in more than 30 years.

“This new technology challenges the traditional approach of placing implants in generic safe zones,” said James Huddleston III, MD, associate professor of orthopaedic surgery at the Stanford University Medical Center. “Now we can get more specific and tailor the implant position for each patient. This should help reduce the dislocation rate and even possibly reduce wear.”

Utilizing pre-operative functional simulation and planning and a unique intra-operative positioning system that employs 3D printing and laser guidance, OPS helps surgeons determine the best position and orientation for a hip implant based on specific patient anatomy and movement.

“While hip replacement surgery is considered one of the most successful operations in medical history, we are always looking for ways to improve it, particularly ways we can improve function and performance and reduce the potential for dislocation and premature wear of bearing surfaces,” said Douglas Dennis, MD, an orthopaedic surgeon in Denver, CO. “This new technology may be an advance that helps us do this.”

In the U.S., the first-ever functional, patient-specific hip replacement procedures using OPS were performed in November 2016, shortly after FDA clearance. More than 3,000 procedures have been done in Europe and Australia, where the system was previously approved for use.

“No two patients are the same. We are offering a patient-specific solution that gives the surgeon the information and tools necessary to enable an optimal hip replacement procedure,” said Paul Berman, President Corin USA. “Feedback from surgeons who have used OPS has been excellent and interest in the system from the orthopaedic community is very high.”

About Corin Group

Corin is a European orthopaedic manufacturer based in the UK that markets its products throughout the world.

Corin is committed to:

…improving patient satisfaction with personalized technologies that optimize our clinically proven joint replacements
…delivering a personal approach to our customers, combining the spirit of our local companies with the strength of our global, integrated organization
…empowering and rewarding our global talented teams to deliver excellence to our customers

For further information about Corin, please visit www.coringroup.com.

This news release contains forward-looking statements. These statements appear in a number of places in this news release and include statements regarding our intentions, beliefs or current expectations, concerning, among other things, our results of operations, turnover, financial condition, liquidity, prospects, growth, strategies, new products, the level of new launches and the markets in which we operate. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ markedly from those in the forward-looking statements as a result of various factors. We undertake no obligation publicly to revise any forward-looking statements, except as may be required by law.

SOURCE Corin USA

Related Links

http://www.coringroup.com

March 14, 2017

SAN DIEGO, Calif., March 14, 2017 /PRNewswire-USNewswire/ — A new study being presented today at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), found that 96.4 percent of recreational athletes, age 55 and younger, who underwent total shoulder replacement surgery returned to at least one sport, on average, within seven months of surgery.

Today, about 53,000 people in the U.S. have shoulder replacement surgery each year, according to the U.S. Agency for Healthcare Research and Quality. This compares to more than 900,000 Americans a year who have hip and knee replacement surgery. In shoulder replacement surgery, the damaged parts of the shoulder are removed and replaced with artificial components, called a prosthesis. A total shoulder replacement involves replacing the arthritic joint surfaces with a highly polished metal ball attached to a stem, and a plastic socket.

In younger patients, repetitive movements required in various sporting activities can cause early osteoarthritis, or wear and tear of the joint, resulting in the need for a replacement.

In this study, researchers conducted a retrospective review of 61 patients who underwent a total shoulder replacement. The average age at the time of surgery was 48.9 years (ages 25 to 55), of which most of the shoulder damage (80.3 percent) was caused by osteoarthritis. Nearly 68 percent of patients said they hoped to return to sports following surgery.

Among the study highlights:

• Ninety-three percent of patients were satisfied with the outcomes of their surgery, and 96.4 percent (55 out of 57 patients) returned to at least one sport at an average of 6.7 months following surgery.
• The direct rates of return to sports included: fitness sports (97.2 percent), golf (93.3 percent), singles tennis (87.5 percent), swimming (87.5 percent), basketball (75 percent) and flag football (66.7 percent).
• More than 90 percent of patients returned to a high-demand sport and 83.8 percent returned to a sport that required high use of the arms and shoulders.
• There was no significant difference in the rate of return to sport by body mass index, sex, age, preoperative diagnosis, revision status and/or dominant extremity.

“Our results evaluated patients at an average of five years of follow up and most patients continued to be very satisfied and performed a high number of sporting activities, including those that required high use of their shoulders,” said study author Grant Garcia, MD, an orthopaedic surgeon at the Hospital for Special Surgery (HSS) in New York. “This information is important as it demonstrates that total shoulder arthroplasty may be a good option in younger patients who are indicated for a shoulder replacement.”

The study, “High satisfaction and return to sports after total shoulder arthroplasty: age 55 and younger,” appeared in the Sept. 28, 2016 issue of the World Journal of Orthopaedics.

Study abstract

2017 AAOS Annual Meeting Disclosure Statements

The American Academy of Orthopaedic Surgeons
With more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world’s largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.

Visit AAOS at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.com/AAOS1
Twitter.com/AAOS1

CONTACT: Sheryl Cash, 847-384-4032, 847-804-7486, scash@aaos.org | Lauren Pearson Riley, 847-384-4031, 708-227-1773, pearson@aaos.org

This information is being sent to you by:
American Academy of Orthopaedic Surgeons
9400 W. Higgins Road, Rosemont, IL , 60018,
http://www.aaos.org

SAN DIEGO, Calif., March 14, 2017 /PRNewswire-USNewswire/ — Despite higher costs, many doctors recommend and some patients prefer, recovery at an in-patient rehabilitation facility following total hip (THR) or total knee replacement (TKR) surgery. And yet a new study to be presented Thursday, March 16, at the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), found that even patients who live alone can recover effectively and safely at home.

“In the past, most surgeons have been reticent to discharge patients directly home after joint replacement surgery if they live by themselves; instead, opting for such patients to enter a rehab facility,” said lead author William J. Hozack, MD, an orthopaedic surgeon at The Rothman Institute and professor of orthopaedic surgery at the Sidney Kimmel Medical College at Thomas Jefferson University. “However, we found that patients living alone were able to safely recover without any increase in the rate of complications. Even more strikingly, patients were generally happy and content being in the comfort of their own home during recovery.”

The study, “Even if You Live Alone, There’s No Place Like Home after Total Joint Arthroplasty,” (LINK) involved 769 patients undergoing primary THR or TKR. Of these, 138 patients lived alone and 631 lived with other people. In both groups, patients age 75 and older were well represented. The patients who lived alone were more likely to stay an additional night in the hospital prior to discharge and utilize more home health services, especially older patients. Limited support without weekly visits was reported by 37.2 percent of patients living alone, although nearly 80 percent had a friend or relative living within 15 miles who could provide help if needed.

Among the results of the study:

• There was no increase in complications or unplanned clinical events for patients living alone compared to those living with other people (10.9 percent of patients living alone had complications, compared with 9.5 percent of those recovering at home with support).
• There were no significant differences in functional outcomes following surgery, or in reported pain.
• Patient satisfaction scores were equivalent in both sets of patients after 90 days.
• The cost savings for patients who recovered at home was estimated at $10,776 per patient, or nearly $1.5 million total.

Given the cost savings of in-home recovery, the emotional benefits of patients recovering in familiar surroundings, and no measurable difference in pain, complications or functional outcomes, “we believe home discharge is appropriate for the vast majority of patients undergoing joint replacement, including the nearly 20 percent of patients living on their own,” said Dr. Hozack.

In addition, the July 2016 U.S. Department of Health & Human Services (HHS) Office of Inspector General report, “Adverse Events in Rehabilitation Hospitals: National Incidence Among Medicare Beneficiaries,” highlighted “a surprisingly high rate of adverse events at rehab hospitals across the U.S.,” said Dr. Hozack.

Study abstract

Two additional studies presented at the 2017 AAOS Annual Meeting also found higher rates of complications and morbidity in hip and knee replacements patients who recover at inpatient care facilities:

• “Continued Inpatient Care after Primary TKA Increases 30-day Post Discharge Complications: A Propensity Score-Adjusted Analysis.”
• “Discharge to Continued Inpatient Care after Total Hip Arthroplasty is Associated with Increased Post-Discharge Morbidity: A Propensity-Adjusted Cohort Study.”

2017 AAOS Annual Meeting Disclosure Statements

The American Academy of Orthopaedic Surgeons
With more than 39,000 members, the American Academy of Orthopaedic Surgeons (AAOS) is the world’s largest association of musculoskeletal specialists. The AAOS provides education programs for orthopaedic surgeons and allied health professionals, champions and advances the highest musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments, and related issues.

Visit AAOS at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.com/AAOS1
Twitter.com/AAOS1

CONTACT: Sheryl Cash, 847-384-4032, 847-804-7486, scash@aaos.org | Lauren Pearson Riley, 847-384-4031, 708-227-1773, pearson@aaos.org

This information is being sent to you by:
American Academy of Orthopaedic Surgeons
9400 W. Higgins Road, Rosemont, IL , 60018,
http://www.aaos.org

I first got to know Curt Wiedenhoefer in 1988 when we were both working with Richards Medical, now Smith & Nephew.  He was a young salesman working in Southern California selling trauma and hip and knee products. Since that time, Curt was recruited to Depuy in Northern California to manage the sales efforts for one of the largest distributorships at the time in the U.S.  While he was working closely with surgeons, he realized there was a need for medical electronics in orthopedics. He founded a company, called Eisenlohr Technologies, Inc. in 1992.  They developed a hand held measuring device for radiographs and an X-Ray marker.  He bootstrapped the product development by collaborating with the PhD electrical engineering program at Stanford University.  Self-funding with a small group of investors, he was able to get the product to market and sold it worldwide. Over the last 12 years he served as the Executive Vice President of Sales and Marketing for Consensus Orthopedics. The past 2 years he has also been the General Manager of the TracPatch division, which focuses on wearable technology in orthopedics.  Recently, he was promoted to President of the Consensus Orthopedics.

I sat down with Curt and asked him a few questions about the new technology Consensus is developing.

1. So Curt, tell me about Consensus Orthopedics and its current trajectory.

Thank you Tiger. We are excited to say this year Consensus will celebrate 25 years in orthopedics!  Our company headquarters is in El Dorado Hills, CA, about 30 miles east of Sacramento in Northern California.  Our primary focus has always been on the hip and knee market and we have been and will continue to be, a high quality and reliable US joint manufacturer. We continued to expand our joint line by launching two new products this year, a Uni Knee and Shoulder. We are a start to finish manufacturing facility from raw materials through sterilization and packaging. We distribute to more than 15 countries worldwide.

Our future is looking bright. In 2015, we founded a medtech division within Consensus named TracPatch. The goal of this division is to use our 25 years of orthopedic experience to create innovative wearable technology for joint replacement rehabilitation and to assist our surgeons through the entire episode of care.

2. Why is Consensus, a traditionally orthopedic implant company, branching out into post-op patient monitoring?

The beginning of TracPatch is an interesting story. I was at a friend’s birthday party and I was talking with an orthopedic surgeon I knew. We were engrossed in the topic of real time post-op patient data. He told me he could “put in the best implant technology, align the joint perfectly, and balance the soft tissues, but if his patient sits on their couch with a pillow under their knee during those critical first six weeks post-operatively, the patient will have a bad result.” The TracPatch spark was lit right then.

From there, we combined our employees’ knowledge of orthopedics and electronics and created the TracPatch Division.

At the same time, CJR was being finalized. So this casual party conversation combined with the market shifting towards a value based model led to our discovering a need for post-op patient monitoring. This was critical to a healthcare providers and/or hospitals success. We leveraged our proximity to Silicon Valley and felt that we could develop products that potentially could improve outcomes, reduce cost and enhance patient satisfaction after total joint surgery. As a result, we created our TracPatch Division, and developed TracPatch, a wearable device for total joint rehabilitation patients.

3. Give me some more details about TracPatch.

TracPatch is a wearable device that can be utilized with any total knee system.  It is placed just below the tibia joint line, medial or lateral to the midline, using a disposable adhesive pad. TracPatch is designed to remotely monitor range of motion, ambulation, exercise compliance, and temperature trends during post-surgical rehabilitation. This machine learning technology strategically optimizes the patient’s entire episode of care with a proactive approach. The TracPatch system includes an app and web dashboard. The app features an intuitive interface for easy operation on any smart phone with Bluetooth technology. The device transmits key data points directly to a secure cloud-based platform, where healthcare providers can track individual patient progress anytime on the app or web dashboard.

← OrthoStreams home

SALT LAKE CITY, March 9, 2017 /PRNewswire/ — OrthoGrid Systems, Inc., a leading innovator of medical imaging technology for orthopedics, is excited to announce its exhibition at Booth #649 on March 15-17 at the American Association of Orthopedic Surgeons (AAOS) 2017 Annual Meeting in San Diego, CA.

OrthoGrid will be showcasing its unique and proprietary HipGrid™ System, a patented image-enhancement device engineered to help orthopedic surgeons improve acetabular cup angle, leg length, and hip offset.  The HipGrid™ System has also been shown to reduce average surgical time and is widely utilized in the Direct Anterior Approach Hip Arthroplasty, a fast-growing technique that accounts for nearly a third of all hip replacement surgeries in the USA.¹

In addition to the HipGrid™ System technical exhibit, OrthoGrid is pleased to offer an educational lecture by renowned physician John Masonis, MD, of OrthoCarolina in Charlotte, NC, in which he will discuss the effective use of fluoroscopy in Direct Anterior Approach Hip Arthroplasty and the proper application of OrthoGrid’s HipGrid™ System.

“OrthoGrid’s unique HipGrid™ System has tremendous potential to aid physicians with implant positioning and component placement in total hip arthroplasty procedures.  By attaching directly to mobile C-Arm systems and providing instantaneous feedback, surgeons can anticipate greater confidence in limb alignment and leg length, two key metrics that directly influence surgical outcomes and patient satisfaction,” explained Edouard Saget, President of OrthoGrid Systems.”

The HipGrid™ is available for sale in the USA through OrthoGrid’s rapidly expanding distributor network.  Please visit our website at www.orthogrid.com to learn more about our company and how to schedule a free product trial.

Reference: Gililland JM, Anderson LA, Boffeli SL, Pelt CE, Peters CL & Kubiak EN. 2012. A Fluoroscopic Grid in Supine Total Hip Arthroplasty: Improving Cup Position, Limb Length and Hip Offset. J Arthroplasty, Sep 27 (8 Suppl): 111-6.

About OrthoGrid Systems, Inc.
OrthoGrid Systems is a rapidly expanding global leader in orthopedic imaging technology with specialized applications available or in development for hip arthroplasty, trauma, knee replacement, and other common procedures performed over 1 million times per year in aggregate in the USA and 3 million times globally.  OrthoGrid helps to overcome the limitations of traditional low resolution, distorted imaging technology by providing computerized image correction and image guidance direction to physicians performing orthopedic procedures.  Learn more about OrthoGrid and our products by visiting our website at www.orthogrid.com.

Media Contact: Edouard Saget, President
Email: 149737@email4pr.com
Phone: 801-703-5866

SOURCE OrthoGrid Systems

Related Links

http://www.orthogrid.com